The shingles vaccine (Shingrix) is one of the most effective vaccines available for adults, providing 94% protection against shingles for people aged 50 and older. Even among adults 70 and older, where immune function naturally declines, efficacy remains at roughly 91%. These numbers come from the full two-dose series, and they hold up well in both clinical trials and real-world studies.
Protection by Age Group
Shingrix works remarkably well across the age range it’s designed for. In adults 50 and older, the vaccine prevents 94% of shingles cases and 91% of postherpetic neuralgia, the burning nerve pain that can linger for months or years after the rash clears. For adults 70 and older, those numbers dip only slightly to 91% and 89%, respectively. That kind of consistency across age groups is unusual for a vaccine and is one of the main reasons Shingrix replaced the older shingles vaccine, Zostavax, which lost effectiveness more steeply with age.
The comparison between the two vaccines is striking. Indirect analyses estimate Shingrix provides roughly 84% greater protection than Zostavax did. Zostavax was discontinued in the U.S. in 2020, and if you received it years ago, you’re still recommended to get the Shingrix series for stronger, longer-lasting protection.
Why Both Doses Matter
Shingrix requires two doses, typically spaced 2 to 6 months apart. Skipping the second dose significantly undermines your protection. Among adults who received only one dose, effectiveness dropped rapidly after the first year and fell to just 52% by year three. That’s a steep decline compared to the sustained protection the full series provides. If more than six months have passed since your first dose, you don’t need to start over. Just get the second dose as soon as you can.
How Long Protection Lasts
Long-term follow-up data now extends out to 10 years after vaccination, and the results are encouraging. Protection stays above 83% through year eight, then gradually decreases to about 73% by years nine and ten. At year four, efficacy sits at roughly 90%. So while the vaccine does lose some potency over time, it still cuts your risk of shingles by nearly three-quarters a full decade after you received it. That’s a meaningful level of protection, especially considering that shingles becomes more common and more severe with age.
There is no current recommendation for a booster dose, though this may change as more long-term data becomes available.
Effectiveness for Immunocompromised Adults
People with weakened immune systems are at higher risk for shingles and tend to have more severe cases. Shingrix still works for this group, though not as well as it does for healthy adults. Overall, the vaccine provides about 60% protection in immunocompromised individuals. The numbers vary depending on the specific condition: efficacy reaches 68% in people who’ve had stem cell transplants and 87% in those with blood cancers like lymphoma or leukemia.
The CDC recommends Shingrix for immunocompromised adults starting at age 19, not 50. The dosing schedule can also be compressed. If there’s a clinical reason to complete the series faster, the second dose can be given as early as one to two months after the first instead of the standard two to six months.
If You’ve Already Had Shingles
Having shingles once doesn’t prevent you from getting it again. The virus that causes shingles, varicella-zoster, stays dormant in your nerve cells permanently and can reactivate more than once. Vaccination after a shingles episode helps reduce the chance of recurrence. The CDC recommends the same two-dose Shingrix series for people who’ve already had shingles, with no required waiting period specified, though many providers suggest waiting until the rash has fully resolved before starting the series.
Who Should Get Vaccinated
The CDC recommends Shingrix for all adults 50 and older, regardless of whether they remember having chickenpox. About 99% of Americans born before 1980 carry the virus, even if they never had noticeable symptoms. The recommendation also covers adults 19 and older who are immunocompromised due to disease or medication, including those on chemotherapy, long-term steroids, or immunosuppressive drugs for autoimmune conditions.
Side effects are common but short-lived. Most people experience soreness at the injection site, and some report fatigue, muscle pain, or low-grade fever for a day or two after each dose. The second dose tends to cause more noticeable side effects than the first. These reactions are a sign of a strong immune response and typically resolve within 48 to 72 hours.